|
![]() |
|
|
Piperazine: profile and news
ImQuest Pharmaceuticals Licenses Piperazine Series of Anti-Cancer ... Apr 26, 2006 Side-effect warning on BZP-based ‘party pills’ Apr 17, 2006 ImQuest licenses anticancer compounds from Samjin Apr 27, 2006 Other information Indication Used as alternative treatment for ascariasis caused by Ascaris lumbricoides(roundworm) and enterobiasis (oxyuriasis) caused by Enterobius vermicularis (pinworm). Pharmacology Piperazine is an antinematodal agent indicated as alternative treatment for ascariasis caused by Ascaris lumbricoides (roundworm) and enterobiasis (oxyuriasis) caused by Enterobius vermicularis (pinworm). Piperazine is especially useful in the treatment of partial intestinal obstruction caused by Ascaris worms, which is a condition primarily seen in children. Mechanism Of Action Piperazine is a GABA receptor agonist. Piperzine binds directly and selectively to muscle membrane GABA receptors, presumably causing hyperpolarization of nerve endings, resulting in flaccid paralysis of the worm. While the worm is paralyzed, it is dislodged from the intestinal lumen and expelled live from the body by normal intestinal peristalsis. Drug Category Antinematodal Agents; Anthelmintics; ATC:P02CB01; ATC:R03DA09 Brand Names/Synonyms Anatensol; Antepan; Antepar; Antiren; Asca-Trol No. 3; Bryrel; Dapotum; Diethylenediamine; Diethyleneimine; Dispermine; Entacyl; Eraverm; Fluphenazine Dihydrochloride; Hexahydropyrazine; Lumbrical; Lyogen; Moditen; Multifuge; Omca; Pacinol; Permitil; Piperazidine; Piperazin; Piperazine; Piperazine Anhydrous; Piperazine Citrate; Piperazine, Anhydrous; Pipersol; Prolixin Decanoate; Pyrazine Hexahydride; Pyrazine, Hexahydro-; Siqualone; Tasnon; Tensofin; UN 2579; Upixon; Uvilon; Valamina; Vermex; Vermidol; Worm-Away; Wurmirazin Dosage Forms CAPSULE; DROPS; LIQUID; POWDER; POWDER FOR SOLUTION; SOLUTION; SUSPENSION; SYRUP; TABLET Absorption Rapidly absorbed from the gastrointestinal tract Interactions Not Available Chemical IUPAC Name piperazine Chemical Formula C4H10N2 Half Life Not Available Drug Type Approved Drug # Accession No APRD00225 CAS Registry Number 110-85-0 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |